Zontivity Might Increase ALS Risk, but Certainty Will Be Difficult to Prove
A cardiovascular medication called Zontivity (vorapaxar) may be linked to a slight, but still increased, risk of amyotrophic lateral sclerosis (ALS), according to a review of U.S. Food and Drug Administration (FDA) documents on data from the drug’s clinical studies. While researchers noted that the risk of developing ALS is very…